Patients with localized primary non-tonsillar oral diffuse large B-cell lymphoma exhibit favorable prognosis despite a non-germinal center B-cell-like phenotype

Cancer Science

Volumn 100, Issue 1, 2009, Pages 42-46

  Sato, Yasuharu ^a   Onishi, Naoko ^a   Morito, Toshiaki ^a   Takata, Katsuyoshi ^a   Mizobuchi, Kohichi ^b   Nagatsuka, Hitoshi ^a   Ichimura, Kouichi ^a   Tanaka, Takehiro ^a   Tamura, Maiko ^a   Yoshino, Tadashi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAGAWA ROSAI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; PIRARUBICIN; PREDNISOLONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CELL TYPE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; LARGE CELL LYMPHOMA; MALE; MOUTH CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PHENOTYPE; PROGNOSIS;

EID: 58149307946     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00995.x     Document Type: Article

References (36)

1. Epstein JB, Epstein JD, Le ND, Gorsky M. Characteristics of oral and paraoral malignant lymphoma: A population-based review of 361 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 519-25.
2. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972; 29: 252-60.
3. Shima N, Kobashi Y, Tsutsui K et al. Extranodal non-Hodgkin's lymphoma of the head and neck. A clinicopathologic study in the Kyoto-Nara area of Japan. Cancer 1990; 66: 1190-7.
4. Kolokotronis A, Konstantinou N, Christakis I et al. Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: A clinical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 99: 303-10.
5. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 4052: 503-11.
6. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
7. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 1937-47.
8. Cmillerri-Broet S, Criniere E, Broet P et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: Analysis of 83 cases. Blood 2006; 107: 190-6.
9. Yoshida S, Nakamura N, Sasaki Y et al. Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Mod Pathol 2005; 18: 398-405.
10. Connor J, Ashton-Key M. Gastric and intestinal diffuse large B-cell lymphomas are clinically and immunophenotypically different. An immunohistochemical and clinical study. Histopathology 2007; 51: 697-703.
11. Campo E, Chott A, Kinney MC. Update on extranodal lymphomas. Conclusions of the workshop held by the EAHP and the SH in Thessaloniki. Greece Histopathol 2006; 48: 481-504.
12. Al-Abbadi MA, Hattab EM, Tarawneh MS, Amr SS, Orazi A, Ulbright TM. Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: A study of 18 cases. Mod Pathol 2006; 19: 1521-7.
13. Murase T, Yamaguchi M, Suzuki R et al. Intravascular large B-cell lymphoma (IVLBCL): A clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 2007; 109: 478-85.
14. Kitsoulis P, Vlychou M, Papoudou-Bai A et al. Primary lymphomas of bone. Anticancer Res 2006; 26: 325-38.
15. Ree HJ, Ohsima K, Aozasa K et al. Detection of germinal center B-cell lymphoma in archival specimens: Critical evaluation of Bcl-6 protein expression in diffuse large B-cell lymphoma of the tonsil. Hum Pathol 2003; 34: 610-16.
16. Niitsu N, Okamoto M, Nakamura N et al. Clinicopathologic correlations of stage IE/IIE primary thyroid diffuse large B-cell lymphoma. Ann Oncol 2007; 18: 1203-8.
17. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. Am J Stat Assoc 1958; 53: 457-8.
18. Peto PE, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patients. Br J Cancer 1977; 35: 1-39.
19. Shipp MA. International non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Eng J Med 1993; 329: 987-94.
20. Pileri SA, Dirnhofer S, Went PH et al. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology 2002; 41: 482-509.
21. Chang CC, McClintock S, Cleveland RP et al. Immunohistochemical expression patterns of germinal center and activation B-cell makers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 464-70.
22. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
23. Zucca E, Conconi A, Mughal TI et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the international extranodal lymphoma Study Group. J Clin Oncol 2003; 21: 20-7.
24. Grange F, Bekkenk MW, Wechsler J et al. Prognostic factors in primary cutaneous large B-cell lymphomas: A European multicenter study. J Clin Oncol 2001; 19: 3602-10.
25. Ishikura S, Tobinai K, Ohtsu A et al. Japanese multicenter phase: Study of CHOP followed by radiotherapy in stage I-II 1, diffuse large B-cell lymphoma of the stomach. Cancer Sci 2005; 96: 349-52.
26. Ferreri AJ, Montalbán C. Primary diffuse large B-cell lymphoma of the stomach. Crit Rev Oncol Hematol 2007; 63: 65-71.
27. Kemp S, Gallagher G, Kabani S et al. Oral non-Hodgkin's lymphoma: Review of the literature and World Health Organization classification with reference to 40 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105: 194-201.
28. Solomides CC, Miller AS, Christman RA et al. Lymphomas of the oral cavity: Histology, immunologic type, and incidence of Epstein-Barr virus infection. Hum Pathol 2002; 33: 153-7.
29. Kojima M, Nakamura N, Shimizu K et al. Marginal zone B-cell lymphoma among primary B-cell lymphoma of Waldeyer's ring: Histopathologic and immunohistochemical study of 16 tonsillectomy specimens. Int J Surg Pathol 2008; 16: 164-70.
30. Kojima M, Inagaki H, Motoori T et al. Clinical implications of nodal marginal zone B-cell lymphoma among Japanese: Study of 65 cases. Cancer Sci 2007; 98: 44-9.
31. Leval LD, Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology 2003; 43: 509-28.
32. Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244-51.
33. Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265-72.
34. Hill ME, MacLennan KA, Cunningham DC et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation Study. Blood 1996; 88: 1046-51.
35. Iqbal J, Neppalli VT, Wright G et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 961-8.
36. Wilson WH, Teruya-Feldstein J, Fest T et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997; 89: 601-9.